Pharmacogenomics: Recent Insights - June 4, 2015

Genomics|Features|Pharmacogenomics

Pharmacogenomics

Pharmacogenomics: Recent Insights - June 4, 2015

Information on Specific Medications and Medical Conditions

• Acute Lymphoblastic Leukemia
• Antidepressants
• Aspirin
• Clopidogrel
• Hepatitis
• Lithium
• Metformin
• Neonatal Withdrawal Syndrome
• Opioid
• Statins
• Warfarin

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
Hess GP et al. Genet Res (Camb) 2015 97e13

Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions
Alagoz O et al. The Pharmacogenomics Journal, May 19, 2015

Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing.
Nishimura AA et al. Genet. Med. 2015 Mar 5.

Returning pharmacogenetic secondary findings from genome sequencing: let's not put the cart before the horse
Janssens AC, et al. Genetics in Medicine, May 7, 2015

Evidence required to demonstrate clinical utility of pharmacogenetic testing: The debate continues. 
N K Gillis and F Innocenti. Clinical Pharmacology & Therapeutics (2014); 96 6, 655–657.

Useless until proven effective: The clinical utility of preemptive pharmacogenetic testing. 
A C J W Janssens and P A Deverka  Clinical Pharmacology & Therapeutics (2014); 96 6, 652–654.

Meaningful use of pharmacogenetics. 
M J Ratain and J A Johnson Clinical Pharmacology & Therapeutics (2014); 96 6, 650–652. 

Web resources for pharmacogenomics.
Zhang Guoqing et al. Genomics Proteomics Bioinformatics 2015 Feb 19.

Nurses' communication of pharmacogenetic test results as part of discharge care.
Haga Susanne B et al. Pharmacogenomics 2015 Mar (3) 251-6

Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas.
Dorfman Elizabeth H et al. Pharmacogenomics 2015 Mar (3) 227-37

Evidence-based Pharmacogenomic Testing: Where are we? - October 16, 2014

Editorial: A call for accurate pharmacogenetic labeling: Telling it like it is. 
Wylie Burke, et al. JAMA Internal Medicine, October 13, 2014 

Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. 
Bo Wang, et al. JAMA Internal Medicine, October 13, 2014 

CDC information: How many pharmacogenomics tests have enough evidence to support their use in practice? Check out CDC table of genomic applications stratified by level of evidence

FDA table of pharmacogenomic markers

CDC paper:  Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.
Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.

CDC blog post: Medications for the masses? Why is pharmacogenomics a public health issue?

Pharmacogenomics: Gap Between Research and Practice - September 4, 2014

New study reveals pharmacogenomic  knowledge gaps among physicians, PharmGKB blog post, Aug 29

Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. 
Dickinson Barry, et al.  Pharmacogenomics and personalized medicine, July 2014

Implementation of personalized medicine services in community pharmacies: need for more education.  Alexander KM, et al. J Am Pharm Assoc (2003). 2014 Aug 22:e326-e333.

CDC information: How many pharmacogenomics tests have enough evidence to support their use in practice? Check out CDC evidence based table of genomic applications stratified by level of evidence

FDA table of pharmacogenomic markers

CDC paper:  Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Dotson W et al, Clin Pharmacol Ther. 2014 Apr;95(4):394-402.

CDC blog post: Medications for the masses? Why is pharmacogenomics a public health issue?